The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with
B cell malignancies. Study details include:
Study Duration: 2 years (1 year of enrollment and 1 year of study participation) Treatment
Duration: ADI-001:1 day (single dose); IL-2 (Part 3 only): 14 days Visit Frequency: Daily for
8 days, then Day 10, 12, 14, 21, 28, and Month 3, 6, 9, and 12